277 related articles for article (PubMed ID: 34626666)
21. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
[TBL] [Abstract][Full Text] [Related]
22. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A
J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549
[TBL] [Abstract][Full Text] [Related]
23. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
[TBL] [Abstract][Full Text] [Related]
24. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
25. LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.
Schindlbeck KA; Vo A; Nguyen N; Tang CC; Niethammer M; Dhawan V; Brandt V; Saunders-Pullman R; Bressman SB; Eidelberg D
Cereb Cortex; 2020 May; 30(5):2867-2878. PubMed ID: 31813991
[TBL] [Abstract][Full Text] [Related]
26. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
27. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
[TBL] [Abstract][Full Text] [Related]
28. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
29. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
[TBL] [Abstract][Full Text] [Related]
30. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
[TBL] [Abstract][Full Text] [Related]
31. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report.
Tang Y; Wei L; Wu Z; Xu P; Mo M
BMC Neurol; 2023 Jun; 23(1):226. PubMed ID: 37301871
[TBL] [Abstract][Full Text] [Related]
34. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
[TBL] [Abstract][Full Text] [Related]
35. [Plasma Exosomes in Inherited Forms of Parkinson's Disease].
Kulabukhova DG; Garaeva LA; Emelyanov AK; Senkevich KA; Gracheva EV; Miliukhina IV; Varfolomeeva EY; Timofeeva AA; Schwartsman AL; Shtam TA; Pchelina SN
Mol Biol (Mosk); 2021; 55(2):338-345. PubMed ID: 33871446
[TBL] [Abstract][Full Text] [Related]
36. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Ahamadi M; Mehrotra N; Hanan N; Lai Yee K; Gheyas F; Anton J; Bani M; Boroojerdi B; Smit H; Weidemann J; Macha S; Thuillier V; Chen C; Yang M; Williams-Gray CH; Stebbins GT; Pagano G; Hang Y; Marek K; Venuto CS; Javidnia M; Dexter D; Pedata A; Stafford B; Akalu M; Stephenson D; Romero K; Sinha V;
Clin Pharmacol Ther; 2021 Aug; 110(2):508-518. PubMed ID: 33894056
[TBL] [Abstract][Full Text] [Related]
37. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
[TBL] [Abstract][Full Text] [Related]
38. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
[TBL] [Abstract][Full Text] [Related]
39. The genetic background of Parkinson's disease and novel therapeutic targets.
Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
Expert Opin Ther Targets; 2022 Oct; 26(10):827-836. PubMed ID: 36524726
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 in Parkinson disease: challenges of clinical trials.
Tolosa E; Vila M; Klein C; Rascol O
Nat Rev Neurol; 2020 Feb; 16(2):97-107. PubMed ID: 31980808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
